SELLAS Life Sciences Group, Inc. (SLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.86+1.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SLS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | 0.0 | 1.0 | 7.6 | 1.9 | — | — | — | — | — | 9.3 | 2.5 | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 9.3 | 2.5 | — | — |
| Cost of Revenues | — | — | — | 0.0 | 0.1 | 0.2 | 0.0 | — | — | — | — | — | 1.4 | 0.5 | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | 12.3 | 12.4 | 13.9 | 12.6 | 11.3 | 9.6 | 9.9 | 12.8 | 15.1 | — | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — | 15.7 | 9.3 | 7.3 | 8.8 | 6.1 | — | — | — | — | 14.6 | 3.9 |
| Other Operating Expenses, Total | — | — | — | — | — | — | — | 0.7 | 2.0 | — | — | — | — | — | — | — |
| Operating Income | (35.2) | (28.3) | (31.5) | (37.9) | (42.0) | (25.3) | (17.0) | (19.4) | (29.0) | (23.0) | (16.0) | (34.2) | (43.9) | (28.5) | (34.4) | (3.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Other Non-Operating Income / Expenses | 2.8 | 1.4 | 0.6 | 0.5 | 0.6 | 4.4 | 0.2 | (19.4) | (29.0) | — | 21.0 | (4.4) | 15.6 | (41.8) | (13.2) | 9.1 |
| EBT, Incl. Unusual Items | — | (26.9) | (30.9) | (37.3) | (41.3) | (20.9) | (16.8) | (19.4) | (29.0) | (23.5) | (10.9) | (38.6) | (28.3) | (70.3) | (34.4) | (3.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | (0.2) | (0.0) | (0.1) | (1.4) | 0.3 | 0.0 | 0.4 | 0.0 | 1.1 | (1.1) | — |
| Earnings from Continuing Operations | — | — | — | — | — | — | (16.8) | (19.3) | (27.7) | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (32.5) | (26.9) | (30.9) | (37.3) | (41.3) | (20.7) | (16.8) | (19.3) | (27.7) | (23.8) | (17.7) | (63.9) | (36.6) | (76.7) | (35.0) | (11.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.17) | (0.25) | (0.50) | (1.34) | (2.13) | (1.34) | (2.11) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.17) | (0.25) | (0.50) | (1.34) | (2.13) | (1.34) | (2.11) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 189.2 | 109.1 | 61.2 | 27.8 | 19.4 | 15.5 | 8.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 189.2 | 109.1 | 61.2 | 27.8 | 19.4 | 15.5 | 8.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | (23.0) | (16.0) | (34.1) | (43.8) | (28.2) | (34.3) | (3.2) |
| EBIT | (35.2) | (28.3) | (31.5) | (37.9) | (42.0) | (25.3) | (17.0) | (19.4) | (29.0) | (23.0) | (16.0) | (34.2) | (43.9) | (28.5) | (34.4) | (3.4) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 1.1% | 0.1% | 0.4% | 4.7% | -1.1% | -0.0% | -0.9% | 0.0% | -1.5% | 3.1% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.